Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  tacrolimus
Find trials that include:  Any drugs shown
Results 1-25 of 70 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Double Cord Versus Haploidentical (BMT CTN 1101)
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1101, NCI-2014-00307, 2U10HL069294-11, 715, NCT01597778
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis
Phase: Phase II, Phase I
Type: Treatment
Age: 17 to 70
Trial IDs: 2067.00, NCI-2011-01352, FHCRC-2067.00, 6364, NCT00622895
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NA_00039823 / CIR00009182, NCT01203722
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2012-0249, NCI-2012-01248, NCT01629511
Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 65
Trial IDs: 2012-0506, NCI-2012-02055, NCT01701986
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients with High Risk Myeloid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 65 and under
Trial IDs: 2012-0819, NCI-2013-00993, RP110553-P3), NCT01823198
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, RM00000684-RN00, NCT01875237
Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403
Palifermin in Preventing Graft-versus-Host Disease in Patients with Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 15-C-0067, NCI-2015-00084, 00-C-0000, 150067, NCT02356159
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Inherited Metabolic Disorders
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 00015791, NCI-2011-03853, NCT01372228
Busulfan and Clofarabine Followed by Donor Stem Cell Transplant in Treating Patients with Acute Leukemia or Lymphoma in Remission or Relapse
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0209, NCI-2012-01270, NCI-2009-01649, NCT00990249
Donor Stem Cell Transplant with Mismatched Donors and High-Dose Post-Transplant Cyclophosphamide in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 65
Trial IDs: 2009-0266, NCI-2011-03144, NCT01010217
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2372.00, NCI-2009-01433, 2372, NCT01028716
Start Over